Realizing the promise.

We are at the cusp of a revolution in medicine. Synthetic biology is an entirely new strategy in drug development, affording us the opportunity to design selective and potent living medicines to treat disease. With a team of experienced scientists and executives at the helm, Synlogic is forging new ground to advance this approach and design novel therapeutics to treat unmet medical needs.

null

Aoife Brennan, MB, BCh, BAO, MRCPI

President and Chief Executive Officer
null

Gregg Beloff

Interim Chief Financial Officer
null

Richard Riese, MD, PhD

CHIEF Medical OFFICER
null

DAVID HAVA, PHD

CHIEF SCIENTIFIC OFFICER
null

Adam Thomas

Chief People Officer and Secretary
null

Antoine Awad

Chief Operating Officer
null

Caroline B. Kurtz, PhD

Head of Translational Sciences and Product Development
null

Daniel Rosan

Head of Corporate Finance and Investor Relations
null

Michael Slater

Head of Regulatory Affairs
null

ANDREW MARSH

HEAD OF DEVELOPMENT OPERATIONS